Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 16, 2025

XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide?

View original at finance.yahoo.com
XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide? Tamisclao / Shutterstock.com Quick Read XRP dropped from $3.66 in July 2025 to around $2.00 by December 2025, losing over 45% as 37% of holders sit on unrealized losses U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analysts argue these institutional XRP ETF inflows create a structural bid under XRP

    80% confidence
  • Since mid-November, U.S. XRP ETF inflows amassed over $1 billion and absorbed nearly 1% of XRP's circulating supply

    80% confidence
  • Technical forecasts suggest a break under $2.00 may target $1.90-1.95 initially, with deeper slides to $1.50 possible if the downtrend intensifies

    80% confidence
  • If XRP ETF inflows continue at current trends, the float may shrink by another 2-3% by Q1 2026

    80% confidence
  • The SEC's approval regime and court rulings characterizing XRP as a commodity made it a compliance-friendly token for advisors

    80% confidence
  • XRP could approach its old $3.66 high by late 2026, driven by shrinking exchange float and steady institutional accumulation

    80% confidence
  • Approximately 37% of XRP's circulating supply sits in unrealized loss

    80% confidence
  • This supply squeeze mirrors what happened to Bitcoin after ETF approval—shrinking float, then rallies

    80% confidence

Data points we hold from this source

XRP · unrealized loss percentage37 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com